Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImMucin Vaccine in MUC1-Positive Multiple Myeloma
NCT01232712Phase 2Completed
- Sponsor
- Vaxil Bio Ltd.
- Start
- Sep 2010
- Primary completion
- May 2013
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ImMucin in multiple myeloma (MM), sponsored by Vaxil Bio Ltd. Primary endpoint: Safety of intradermal or subcutaneous administration of the ImMucin peptide at 6 months. Started Sep 2010; status: completed.
02
Drugs
ImMucin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01232712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232712.